BLS Pharmaceuticals Delivers Record FY26 as International Manufacturing Platform Scales
BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising ...
BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising ...
For much of the past decade, Australia's medicinal cannabis industry has been defined by domestic growth. Companies raced to expand ...
© 2026 Psychedelics.media - A division of Dot Media Corp.
© 2026 Psychedelics.media - A division of Dot Media Corp.